Intracellular Accumulation of Nelfinavir and Its Relationship to P-Glycoprotein Expression and Function in HIV-Infected Patients
- 1 January 2004
- journal article
- Published by SAGE Publications in Antiviral Therapy
- Vol. 9 (1) , 115-122
- https://doi.org/10.1177/135965350400900103
Abstract
Objective: To compare plasma and intracellular nelfinavir pharmacokinetics, and determine their relationship to P-glycoprotein (P-gp) expression and function in lymphocytes of HIV-infected patients. Methods: A pharmacokinetic study of 12 patients receiving nelfinavir plus dual nucleoside analogue therapy. Blood samples were taken at intervals to 12 h. Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation, and nelfinavir extracted from cells in the presence of 60% methanol and evaporated to dryness. Both plasma and intracellular nelfinavir samples were assayed by high performance liquid chromatography linked to mass spectrometry. P-gp expression and function were measured by flow cytometric analysis. Data were analysed by non-compartmental analysis using WinNonLin pharmacokinetic software. Results: The mean intracellular nelfinavir AUC0–12 (mean ±SE) was about ninefold higher than that of plasma (264 200 ±63420 vs 29250 ±6629 ng/ml/h; Pmin and C0 values for nelfinavir were five- to sixfold higher than that of plasma (Cmin: 5712 ±2156 vs 1062 ±357 ng/ml; C0: 15860 ±3662 vs 2553 ±539 ng/ml; Pmax was 15-fold higher than plasma (59420 ±13940 vs 3986 ±822 ng/ml; Pmax, elimination half-life or mean residence time. In patients chronically treated with nelfinavir mean P-gp expression was 8.85 ±1.3 MFI, there was no correlation between Pgp expression and either intracellular AUC0–12 (r=–0.35; P=0.29) or intracellular C0 values. There was a correlation between intracellular nelfinavir concentrations and P-gp function at baseline (r=0.59; P0–12 for nelfinavir (r=0.75; P=0.011). Conclusions: Nelfinavir undergoes significant intracellular accumulation within the PBMCs of HIV-infected patients, which may be in part related to its moderate ability to inhibit P-gp-mediated drug efflux. The addition of ritonavir further reduced P-gp function. Intracellular accumulation of nelfinavir correlated with P-gp function but not P-gp expression, suggesting pump activity is substrate concentration-dependant. There was a significant correlation between plasma and intracellular nelfinavir concentrations, suggesting one is a good surrogate marker of the other.Keywords
This publication has 41 references indexed in Scilit:
- Interdependent Effect of P-Glycoprotein-Mediated Drug Efflux and Intracellular Drug Binding on Intracellular Paclitaxel Pharmacokinetics: Application of Computational ModelingThe Journal of Pharmacology and Experimental Therapeutics, 2003
- St John's Wort increases expression of P‐glycoprotein: Implications for drug interactionsBritish Journal of Clinical Pharmacology, 2002
- Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitorsAIDS, 2000
- Antiviral Effect and Pharmacokinetic Interaction between Nevirapine and Indinavir in Persons Infected with Human Immunodeficiency Virus Type 1The Journal of Infectious Diseases, 1999
- Relationships Between Exposure to Saquinavir Monotherapy and Antiviral Response in HIV-Positive PatientsClinical Pharmacokinetics, 1999
- Pharmacokinetics and Potential Interactions Amongst Antiretroviral Agents Used To Treat Patients with HIV InfectionClinical Pharmacokinetics, 1999
- P‐Glycoprotein‐Mediated Hoechst 33342 Transport Out of the Lipid BilayerEuropean Journal of Biochemistry, 1997
- Examination of multidrug resistance in cell lines and primary breast tumours by flow cytometryEuropean Journal Of Cancer, 1996
- In vivo emergence of HIV-1 variants resistant to multiple protease inhibitorsNature, 1995
- P-Glycoprotein Expression in Acute Myeloblasts Leukemia Analyzed by Immunocytochemistry and Flow CytometryLeukemia & Lymphoma, 1995